DiscoveryProbe™ FDA-approved Drug Library: Redefining Drug Repositioning via Epigenetic and Enzyme Inhibitor Screening

Introduction

Drug discovery is experiencing a paradigm shift driven by the need for accelerated therapeutic development, rational target identification, and robust translational outcomes. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) from APExBIO stands at the forefront of this transformation, offering a meticulously curated collection of 2,320 bioactive compounds that have received clinical approval from leading regulatory agencies (FDA, EMA, HMA, CFDA, PMDA) or are listed in major pharmacopeias. Unlike traditional libraries, this high-throughput screening drug library is uniquely positioned for high-content screening, drug repositioning, and advanced pharmacological target identification—especially for applications requiring mechanistic depth such as enzyme inhibitor screening and epigenetic modulation.

Unique Mechanistic Focus: Beyond Conventional Screening

While previous reviews of the DiscoveryProbe FDA-approved Drug Library have explored its utility in unveiling hidden therapeutic opportunities and mapping mTORC1 signaling pathways in cancer and neurodegenerative disease contexts, this article provides a distinct analytical approach. We delve into the library’s capacity to interrogate epigenetic mechanisms and enzyme inhibition—two pillars underpinning next-generation drug repositioning and disease model interrogation. In particular, we dissect the role of the library in facilitating the discovery of novel non-oncological uses for approved drugs, with an emphasis on cancer metastasis and neurodegenerative disease research via high-content screening compound collections.

Mechanism of Action: Epigenetic and Enzyme Inhibitor Profiling

The Library Composition and Format

Each compound in the DiscoveryProbe™ FDA-approved Drug Library is supplied as a 10 mM pre-dissolved solution in DMSO, available in versatile formats—96-well microplates, deep-well plates, or 2D barcoded screw-top storage tubes. This ensures compatibility with automation-driven workflows for high-throughput and high-content screening (HTS/HCS). The compounds remain stable for 12 months at -20°C and up to 24 months at -80°C, supporting longitudinal studies and reproducibility.

Targeting Epigenetic Regulation and Enzyme Inhibition

Epigenetic modifications—particularly non-histone acetylation—play a critical role in gene expression, DNA repair, and cellular signaling. Enzymes such as histone deacetylases (HDACs) are central to these processes. The DiscoveryProbe FDA-approved Drug Library includes a spectrum of receptor agonists, antagonists, ion channel modulators, and—most notably—enzyme inhibitors, enabling systematic screening of compounds with potential to modulate epigenetic landscapes.

A landmark study by Jiang and Ma (2022) demonstrated this potential by identifying canagliflozin, a clinically approved SGLT2 inhibitor, as a potent HDAC6-targeted inhibitor from within an FDA-approved bioactive compound library (DOI:10.3389/fonc.2022.1057455). Utilizing enzymatic assays, surface plasmon resonance (SPR), cellular thermal shift assays (CETSA), and molecular docking, the study revealed that canagliflozin binds HDAC6, inhibits its activity, and suppresses gastric cancer metastasis by reversing epithelial-mesenchymal transition (EMT) markers. These findings underscore how enzyme inhibitor screening within a curated compound collection can yield actionable insights into both oncogenic and non-oncogenic disease mechanisms.

Comparative Analysis: DiscoveryProbe™ Versus Traditional and Mechanism-Driven Libraries

Mechanism-driven drug discovery is transforming how researchers approach pharmacological target identification and drug repositioning screening. Compared to generic chemical libraries, the DiscoveryProbe™ FDA-approved Drug Library provides several key advantages:

• Clinical Relevance: All compounds are approved or listed in recognized pharmacopeias, facilitating rapid translational research and reducing barriers to clinical application.
• Mechanistic Diversity: The library encompasses drugs with diverse mechanisms—receptor modulation, ion channel targeting, enzyme inhibition, and signal pathway regulation—enabling multi-dimensional screening for both known and novel targets.
• Repositioning Potential: Since the safety and pharmacokinetic profiles of these compounds are well characterized, candidates identified via high-content screening can move swiftly into preclinical and clinical development for new indications.
• Data Integration: High-throughput and high-content compatibility allows for integration with omics and phenotypic data, supporting systems biology approaches.

This focus on mechanistic and translational depth distinguishes the library from more general approaches, as discussed in the phenotypic screening-centric review. Here, our spotlight remains on epigenetic and enzyme inhibitor screening as engines for new target discovery and disease model development.

Advanced Applications in Cancer and Neurodegenerative Disease Research

Cancer Research: Metastasis and EMT Inhibition

The clinical challenge of cancer metastasis—particularly in gastric cancer—remains formidable. Traditional chemotherapeutics often fail to address metastatic spread, necessitating more targeted approaches. As the canagliflozin study exemplifies (Jiang & Ma, 2022), high-content screening using FDA-approved bioactive compound libraries can pinpoint existing drugs with unanticipated anti-metastatic activity by targeting key epigenetic regulators such as HDAC6. This strategy not only uncovers new cancer therapeutics but also elucidates the mechanistic underpinnings of metastasis, opening avenues for combinatorial regimens and personalized medicine.

Importantly, our approach diverges from earlier mechanism-focused overviews—such as the article on strategic pathways for metallo-β-lactamase inhibitor discovery—by emphasizing epigenetic and enzyme inhibition mechanisms, and their translational relevance to metastasis and EMT, rather than focusing solely on resistance or cell death pathways.

Neurodegenerative Disease Drug Discovery

Epigenetic dysregulation and aberrant enzyme activity are increasingly recognized as contributors to neurodegenerative diseases such as Alzheimer's and Parkinson's. The DiscoveryProbe™ FDA-approved Drug Library enables systematic screening for compounds that modulate neuronal signaling pathways, synaptic plasticity, and protein aggregation via enzyme inhibition and signal pathway regulation. Since the library’s compounds include agents with known blood-brain barrier penetration and established safety profiles, positive hits can be prioritized for rapid preclinical validation in neurodegeneration models.

Drug Repositioning: From Bench to Bedside

Drug repositioning screening is especially potent when leveraging clinically characterized compound libraries. The DiscoveryProbe™ FDA-approved Drug Library supports the identification of candidates for orphan and rare diseases, where traditional HTS libraries may lack relevant clinical context or mechanistic breadth. By integrating high-throughput screening with advanced bioinformatics and machine learning, researchers can mine for repurposing opportunities that intersect with emerging disease mechanisms, including those involving epigenetic regulation and enzyme inhibition.

Technical Implementation: Maximizing Utility in Screening Workflows

Sample Handling and Stability: The library’s pre-dissolved DMSO solutions, distributed in automation-friendly formats, enable seamless integration into robotics-based screening platforms. Storage at -20°C (12 months) or -80°C (24 months) ensures compound integrity, while flexible shipping options (blue ice or room temperature) accommodate varied laboratory requirements.

Data Analysis and Validation: High-content readouts—such as cell-based phenotypic assays, fluorescent reporter endpoints, and transcriptomic profiling—can be directly coupled with the library’s screening outputs. Hits identified via enzyme inhibitor screening or epigenetic modulation can be rapidly validated in relevant in vitro and in vivo models, as illustrated by the canagliflozin/HDAC6 example.

Strategic Integration with Existing Knowledge

Whereas previous articles have explored mechanistic cell death pathways and advanced phenotypic screening, this article provides a differentiated, application-centric perspective—focusing on how epigenetic and enzyme inhibitor screening within a clinically curated library accelerates drug repositioning and target identification. The emphasis on integrative methodologies, such as combining high-content screening with omics datasets and computational modeling, reflects the evolving landscape of translational drug discovery.

Conclusion and Future Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is more than a collection of bioactive compounds—it is a catalyst for next-generation drug repositioning, pharmacological target identification, and mechanistic disease modeling. By enabling high-throughput screening with a focus on epigenetic regulation and enzyme inhibition, the library empowers researchers to uncover novel therapeutic strategies for cancer, neurodegenerative, and rare diseases. The translational potential is exemplified by recent breakthroughs such as the identification of canagliflozin as a HDAC6 inhibitor suppressing gastric cancer metastasis (Jiang & Ma, 2022).

As the field advances, integrating this high-content screening compound collection with modern computational, phenotypic, and systems biology approaches will further accelerate the journey from bench to bedside. Researchers seeking to harness the full power of clinically relevant, mechanistically diverse libraries will find DiscoveryProbe™ an indispensable resource for both foundational and translational life sciences research.